MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors
- PMID: 16796815
- PMCID: PMC3933137
- DOI: 10.1111/j.1582-4934.2006.tb00415.x
MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors
Abstract
The goal of our study was to analyse the prognostic values for some matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in breast cancer. We evaluated the activity and the expression levels of MMP-9, MMP-2, TIMP-1 and TIMP-2 in malignant versus benign fresh breast tumor extracts. For this purpose, gelatinzymography, immunoblotting and ELISA were used to analyse the activity and expression of MMPs and TIMPs. We found that MMP-9 expression level and activity are increased in malignant tumors. In addition, MMP-9/TIMP-1 and MMP-2/TIMP-2 ratio values obtained by us were significantly different in malignant tumors compared to benign tumors. We suggest that the abnormal MMP-9/TIMP-1 balance plays a role in the configuration of breast invasive carcinoma of no special type and also in tumor growth, while altered MMP-2/TIMP-2 ratio value could be associated with lymph node invasion and used as a prognostic marker in correlation with Nottingham Prognostic Index. Finally, we showed that in malignant tumors high expression of estrogen receptors is associated with enhanced activity of MMP-2 and increased bcl- 2 levels, while high expression of progesterone receptors is correlated with low TIMP-1 protein levels.
Similar articles
-
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.Int J Cancer. 2008 May 1;122(9):2050-6. doi: 10.1002/ijc.23337. Int J Cancer. 2008. PMID: 18172859
-
[Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].Ai Zheng. 2003 Sep;22(9):968-73. Ai Zheng. 2003. PMID: 12969531 Chinese.
-
[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].Ai Zheng. 2004 Oct;23(10):1194-8. Ai Zheng. 2004. PMID: 15473934 Chinese.
-
Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.Clin Breast Cancer. 2018 Feb;18(1):e123-e133. doi: 10.1016/j.clbc.2017.08.008. Epub 2017 Aug 19. Clin Breast Cancer. 2018. PMID: 28927692
-
Matrix metalloproteinases and their inhibitors.Anticancer Res. 1999 Mar-Apr;19(2C):1589-92. Anticancer Res. 1999. PMID: 10365151 Review.
Cited by
-
Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study.Oncotarget. 2019 Dec 3;10(64):6879-6884. doi: 10.18632/oncotarget.27347. eCollection 2019 Dec 3. Oncotarget. 2019. PMID: 31839881 Free PMC article.
-
Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.Discov Oncol. 2024 Dec 18;15(1):783. doi: 10.1007/s12672-024-01693-8. Discov Oncol. 2024. PMID: 39692932 Free PMC article. Review.
-
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.Clin Cancer Res. 2008 Oct 15;14(20):6610-7. doi: 10.1158/1078-0432.CCR-08-1136. Clin Cancer Res. 2008. PMID: 18927302 Free PMC article.
-
Comparing CD10 Expression With the Clinicopathological Features and Hormone Status of Invasive Breast Cancer.Cureus. 2024 Sep 21;16(9):e69836. doi: 10.7759/cureus.69836. eCollection 2024 Sep. Cureus. 2024. PMID: 39435217 Free PMC article.
-
PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-κB/MMP-9 signaling pathway.Mol Cancer. 2015 Mar 26;14:66. doi: 10.1186/s12943-015-0332-2. Mol Cancer. 2015. PMID: 25888829 Free PMC article.
References
-
- Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4. - PubMed
-
- Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet. 1990;6:121–5. - PubMed
-
- Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151–60. - PubMed
-
- Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998;12:1075–95. - PubMed
-
- Benz CC. Transcriptional factors and breast cancer. Endoc Rel Cancer. 1998;5:271–82.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous